E. Premkumar Reddy

E. Premkumar Reddy's AcademicInfluence.com Rankings

E. Premkumar Reddy

Biology

#1374

World Rank

#2311

Historical Rank

Molecular Biology

#153

World Rank

#157

Historical Rank

Genetics

#367

World Rank

#429

Historical Rank

biology Degrees

Download Badge

Biology

E. Premkumar Reddy's Degrees

PhD Genetics Delhi University
Masters Genetics Delhi University
Bachelors Botany Delhi University

Why Is E. Premkumar Reddy Influential?

(Suggest an Edit or Addition)

According to Wikipedia, E. Premkumar Reddy is a molecular biologist specialising in molecular oncology. He is the Director of Experimental Cancer Therapeutics program and Professor in the Departments of Oncological Sciences and Structural and Chemical Biology at the Mount Sinai School of Medicine.

(See a Problem?)

E. Premkumar Reddy's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

JNK signaling in apoptosis (2008) (1298)
A point mutation is responsible for the acquisition of transforming properties by the T24 human bladder carcinoma oncogene (1982) (1245)
Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). (1995) (1204)
Loss of Cdk4 expression causes insulin-deficient diabetes and Cdk4 activation results in β-islet cell hyperplasia (1999) (760)
Modulation of life and death by the TNF receptor superfamily (1998) (596)
The myb gene family in cell growth, differentiation and apoptosis (1999) (503)
Expression of cellular homologues of retroviral onc genes in human hematopoietic cells. (1982) (486)
Drugging the 'undruggable' cancer targets (2017) (477)
Janus kinases: components of multiple signaling pathways (2000) (465)
Cellular genes analogous to retroviral onc genes are transcribed in human tumour cells (1982) (454)
Transducers of life and death: TNF receptor superfamily and associated proteins. (1996) (437)
Malignant activation of a K-ras oncogene in lung carcinoma but not in normal tissue of the same patient. (1984) (414)
ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent. (2005) (358)
Acquisition of transforming properties by alternative point mutations within c-bas/has human proto-oncogene (1983) (319)
Signaling by dual specificity kinases (1998) (308)
Scaffold proteins of MAP-kinase modules (2007) (297)
HTLV-III gag protein is processed in yeast cells by the virus pol-protease. (1986) (273)
Hematopoietic cytokine receptor signaling (2007) (254)
JAKs, STATs and Src kinases in hematopoiesis (2002) (254)
Nucleotide sequence of the simian sarcoma virus genome: demonstration that its acquired cellular sequences encode the transforming gene product p28sis. (1983) (238)
IL-3 signaling and the role of Src kinases, JAKs and STATs: a covert liaison unveiled (2000) (236)
Arrest of spermatogenesis and defective breast development in mice lacking A-myb (1997) (233)
A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance. (2005) (230)
JNK-signaling: A multiplexing hub in programmed cell death (2017) (223)
A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling (2016) (222)
Gene product of v-fgr onc: hybrid protein containing a portion of actin and a tyrosine-specific protein kinase. (1984) (197)
Jak/STAT pathways in cytokine signaling and myeloproliferative disorders: approaches for targeted therapies. (2010) (197)
Nucleotide sequence of Abelson murine leukemia virus genome: structural similarity of its transforming gene product to other onc gene products with tyrosine-specific kinase activity. (1983) (194)
Germ Line Transmission of the Cdk4R24C Mutation Facilitates Tumorigenesis and Escape from Cellular Senescence (2002) (168)
The Oncogene Handbook (1988) (164)
Chromosomal mapping of the simian sarcoma virus onc gene analogue in human cells. (1982) (162)
Synthesis of new coumarin 3-(N-aryl) sulfonamides and their anticancer activity. (2004) (160)
Src kinases and not JAKs activate STATs during IL-3 induced myeloid cell proliferation (1998) (158)
Truncation of the c-myb gene by a retroviral integration in an interleukin 3-dependent myeloid leukemia cell line. (1986) (153)
JLP: A scaffolding protein that tethers JNK/p38MAPK signaling modules and transcription factors (2002) (148)
DNA rearrangement and altered RNA expression of the c-myb oncogene in mouse plasmacytoid lymphosarcomas. (1983) (142)
JAK3: a novel JAK kinase associated with terminal differentiation of hematopoietic cells. (1994) (140)
CDK4: A Key Player in the Cell Cycle, Development, and Cancer. (2012) (137)
Conditional c-myb knockout in adult hematopoietic stem cells leads to loss of self-renewal due to impaired proliferation and accelerated differentiation (2009) (137)
Role of tryptophan repeats and flanking amino acids in Myb-DNA interactions. (1990) (128)
Activation of the c-myb locus by viral insertional mutagenesis in plasmacytoid lymphosarcomas. (1984) (124)
Regulation of human ornithine decarboxylase expression by the c-Myc.Max protein complex. (1993) (121)
Nucleotide sequence analysis of the T24 human bladder carcinoma oncogene. (1983) (121)
Activation of p38α/β MAPK in myogenesis via binding of the scaffold protein JLP to the cell surface protein Cdo (2006) (115)
Abrogation of interleukin-3 dependence of myeloid cells by the v-src oncogene requires SH2 and SH3 domains which specify activation of STATs (1997) (111)
Nucleotide sequence analysis of the chicken c-myc gene reveals homologous and unique coding regions by comparison with the transforming gene of avian myelocytomatosis virus MC29, delta gag-myc. (1983) (107)
Cyclin-dependent kinase 4 expression is essential for neu-induced breast tumorigenesis. (2005) (106)
Design, synthesis, and biological evaluation of 1-(4-sulfamylphenyl)-3-trifluoromethyl-5-indolyl pyrazolines as cyclooxygenase-2 (COX-2) and lipoxygenase (LOX) inhibitors. (2008) (98)
Stage-Specific Human Induced Pluripotent Stem Cells Map the Progression of Myeloid Transformation to Transplantable Leukemia. (2017) (96)
Disruption of transforming growth factor-β signaling through β-spectrin ELF leads to hepatocellular cancer through cyclin D1 activation (2007) (95)
Abelson murine leukemia virus: molecular cloning of infectious integrated proviral DNA. (1981) (92)
Transforming growth factor-beta suppresses nonmetastatic colon cancer through Smad4 and adaptor protein ELF at an early stage of tumorigenesis. (2005) (92)
Spontaneous activation of a human proto-oncogene. (1983) (92)
The galactosyl ceramide/sulfatide receptor binding region of HIV-1 gp120 maps to amino acids 206-275. (1993) (91)
Requirement of c-myb in T cell development and in mature T cell function. (2004) (91)
Disruption of transforming growth factor-beta signaling through beta-spectrin ELF leads to hepatocellular cancer through cyclin D1 activation. (2007) (89)
Effect of Abelson murine leukemia virus on granulocytic differentiation and interleukin-3 dependence of a murine progenitor cell line. (1987) (88)
Nucleotide sequence of the transforming gene of avian myeloblastosis virus. (1982) (86)
Nucleotide sequence of chicken c-myb complementary DNA and implications for myb oncogene activation (1986) (85)
The ins and outs of bcr-abl inhibition. (2012) (85)
In vivo identification of the transforming gene product of simian sarcoma virus. (1982) (83)
Differential regulation of the retinoblastoma family of proteins during cell proliferation and differentiation. (1998) (82)
Nuclear Pores Promote Lethal Prostate Cancer by Increasing POM121-Driven E2F1, MYC, and AR Nuclear Import (2018) (82)
Nucleotide sequence analysis of the proviral genome of avian myelocytomatosis virus (MC29). (1983) (78)
Mechanism of activation of an N-ras oncogene of SW-1271 human lung carcinoma cells. (1984) (77)
Complete nucleotide sequence and organization of the Moloney murine sarcoma virus genome. (1981) (76)
Discovery of a clinical stage multi-kinase inhibitor sodium (E)-2-{2-methoxy-5-[(2',4',6'-trimethoxystyrylsulfonyl)methyl]phenylamino}acetate (ON 01910.Na): synthesis, structure-activity relationship, and biological activity. (2011) (76)
Multi-unit ribozyme-mediated cleavage of bcr-abl mRNA in myeloid leukemias. (1995) (76)
HTLV-III env gene products synthesized in E. coli are recognized by antibodies present in the sera of AIDS patients (1985) (75)
Murine A-myb: evidence for differential splicing and tissue-specific expression. (1994) (74)
Styryl sulfonyl compounds inhibit translation of cyclin D1 in mantle cell lymphoma cells (2009) (70)
Nucleotide sequence of testis-derived c-abl cDNAs: implications for testis-specific transcription and abl oncogene activation. (1987) (69)
Ribozyme-mediated cleavage of the BCRABL oncogene transcript: in vitro cleavage of RNA and in vivo loss of P210 protein-kinase activity. (1993) (69)
Radiation Protection by a New Chemical Entity, Ex-Rad™: Efficacy and Mechanisms (2009) (69)
Increased expression of myc-related oncogene mRNA characterizes most BALB/c plasmacytomas induced by pristane or Abelson murine leukemia virus. (1983) (68)
AATYK: A novel tyrosine kinase induced during growth arrest and apoptosis of myeloid cells (1997) (66)
Identification of the leukemogenic protein of avian myeloblastosis virus and of its normal cellular homologue. (1983) (63)
JLP Associates with Kinesin Light Chain 1 through a Novel Leucine Zipper-like Domain* (2005) (58)
Cell cycle control of pancreatic beta cell proliferation. (2000) (57)
Myb protein binds to human immunodeficiency virus 1 long terminal repeat (LTR) sequences and transactivates LTR-mediated transcription. (1990) (57)
Discovery of 8-Cyclopentyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidine-6-carbonitrile (7x) as a Potent Inhibitor of Cyclin-Dependent Kinase 4 (CDK4) and AMPK-Related Kinase 5 (ARK5) (2014) (54)
Structural alteration in the MYB protooncogene and deletion within the gene encoding alpha-type protein kinase C in human melanoma cell lines. (1988) (52)
Mutational analysis of Max: role of basic, helix-loop-helix/leucine zipper domains in DNA binding, dimerization and regulation of Myc-mediated transcriptional activation. (1992) (52)
Celecoxib and a novel COX-2 inhibitor ON09310 upregulate death receptor 5 expression via GADD153/CHOP (2008) (50)
Polymorphism of the 3' open reading frame of the virus associated with the acquired immune deficiency syndrome, human T-lymphotropic virus type III. (1985) (50)
Transforming growth factor‐β adaptor, β2‐spectrin, modulates cyclin dependent kinase 4 to reduce development of hepatocellular cancer (2011) (50)
Nucleotide sequence analysis of the transforming region and large terminal redundancies of Moloney murine sarcoma virus. (1980) (46)
Cellular Factors Binding to a Novel cis-Acting Element Mediate Steroid Hormone Responsiveness of Mouse Mammary Tumor Virus Promoter (*) (1995) (46)
Transforming pathways activated by the v-Abl tyrosine kinase (2002) (46)
Differential binding of nuclear factors to the intron 1 sequences containing the transcriptional pause site correlates with c-myb expression. (1989) (46)
The v-myc oncogene (1999) (45)
Aberrant splicing events that are induced by proviral integration: implications for myb oncogene activation. (1987) (45)
Abelson murine leukemia virus: structural requirements for transforming gene function. (1982) (45)
Destabilization of Bcr-Abl/Jak2 Network by a Jak2/Abl Kinase Inhibitor ON044580 Overcomes Drug Resistance in Blast Crisis Chronic Myelogenous Leukemia (CML). (2010) (45)
Critical interactions between TGF-β signaling/ELF, and E-cadherin/β-catenin mediated tumor suppression (2006) (45)
Temporal patterns of A-myb and B-myb gene expression during testis development. (1996) (45)
Structural organization and nucleotide sequence of mouse c-myb oncogene: activation in ABPL tumors is due to viral integration in an intron which results in the deletion of the 5' coding sequences (1986) (44)
Novel coumarin-3-(N-aryl)carboxamides arrest breast cancer cell growth by inhibiting ErbB-2 and ERK1. (2005) (44)
cAMP-induced NF-κB (p50/relB) binding to a c-myb intronic enhancer correlates with c-myb up-regulation and inhibition of erythroleukemia cell differentiation (1997) (44)
An in vivo functional screen uncovers miR-150-mediated regulation of hematopoietic injury response. (2012) (44)
Design, synthesis, and biological evaluation of (E)-styrylbenzylsulfones as novel anticancer agents. (2008) (43)
v-myb blocks granulocyte colony-stimulating factor-induced myeloid cell differentiation but not proliferation (1993) (42)
Different lymphoid cell targets for transformation by replication-competent moloney and rauscher mouse leukemia viruses (1980) (42)
Myb Permits Multilineage Airway Epithelial Cell Differentiation (2014) (41)
Angiomotin stabilization by tankyrase inhibitors antagonizes constitutive TEAD-dependent transcription and proliferation of human tumor cells with Hippo pathway core component mutations (2016) (37)
B-myb is an essential regulator of hematopoietic stem cell and myeloid progenitor cell development (2014) (37)
Complete sequence of a cloned cDNA encoding rabbit secreted mu-chain of VHa2 allotype: comparisons with VHa1 and membrane mu sequences. (1984) (37)
Nucleotide sequence analysis of the BALB/c murine sarcoma virus transforming gene (1985) (37)
Targeted inhibition of kinases in cancer therapy. (2010) (35)
Epigenetic Silencing of β-Spectrin, a TGF-β Signaling/Scaffolding Protein in a Human Cancer Stem Cell Disorder (2010) (35)
A role for the epidermal growth factor receptor signaling in development of intestinal serrated polyps in mice and humans. (2012) (35)
(Z)-1-aryl-3-arylamino-2-propen-1-ones, highly active stimulators of tubulin polymerization: synthesis, structure-activity relationship (SAR), tubulin polymerization, and cell growth inhibition studies. (2012) (35)
JNK-interacting leucine zipper protein is a novel scaffolding protein in the Galpha13 signaling pathway. (2005) (34)
Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay (2009) (34)
A Non-ATP-Competitive Dual Inhibitor of JAK2 and BCR-ABL Kinases: Elucidation of a Novel Therapeutic Spectrum Based on Substrate Competitive Inhibition. (2010) (34)
Molecular cloning of human T-cell lymphotrophic virus type I-like proviral genome from the peripheral lymphocyte DNA of a patient with chronic neurologic disorders. (1988) (33)
ON01210.Na (Ex-RAD®) Mitigates Radiation Damage through Activation of the AKT Pathway (2013) (33)
Effect of ON 01910.Na, an anticancer mitotic inhibitor, on cell-cycle progression correlates with RanGAP1 hyperphosphorylation. (2011) (32)
Inhibition of tumor angiogenesis in vivo by a monoclonal antibody targeted to domain 5 of high molecular weight kininogen. (2004) (31)
Inactivation of ELF/TGF-β signaling in human gastrointestinal cancer (2005) (30)
Activation of the Jak3 pathway is associated with granulocytic differentiation of myeloid precursor cells. (2002) (30)
Alteration of growth and differentiation factors response by Kirsten and Harvey sarcoma viruses in the IL-3-dependent murine hematopoietic cell line 32D C13(G). (1989) (29)
Nucleotide sequence of a radiation leukemia virus genome. (1987) (29)
Molecular cloning of the breakpoint region on chromosome 6 in cutaneous malignant melanoma: evidence for deletion in the c-myb locus and translocation of a segment of chromosome 12. (1989) (29)
Characterization of an alternatively spliced AATYK mRNA: Expression pattern of AATYK in the brain and neuronal cells (2001) (28)
Activation of murine c-abl protooncogene: effect of a point mutation on oncogenic activation. (1990) (27)
Oncogenic mutant of Gα12 stimulates cell proliferation through cycloxygenase-2 signaling pathway (1999) (27)
Mechanisms associated with the generation of biologically active human immunodeficiency virus type 1 particles from defective proviruses. (1991) (27)
Nucleotide sequence of the transforming gene of simian sarcoma virus. (1982) (26)
Anatomy of an integrated avian myeloblastosis provirus: structure and function. (1994) (26)
Design, synthesis and evaluation of (E)-alpha-benzylthio chalcones as novel inhibitors of BCR-ABL kinase. (2010) (25)
Mechanisms associated with IL-6-induced up-regulation of Jak3 and its role in monocytic differentiation. (2004) (25)
The C-Terminal Domain of B-Myb Acts As a Positive Regulator of Transcription and Modulates Its Biological Functions (1998) (24)
The cellular proto-oncogene product Myb acts as transcriptional activator of the long terminal repeat of human T-lymphotropic virus type I (1992) (24)
Regulation of Neurite Outgrowth by Interactions between the Scaffolding Protein, JNK-associated Leucine Zipper Protein, and Neuronal Growth-associated Protein Superior Cervical Ganglia Clone 10 (2009) (23)
Endodermal differentiation of murine embryonic carcinoma cells by retinoic acid requires JLP, a JNK‐scaffolding protein (2006) (23)
Rigosertib is a more effective radiosensitizer than cisplatin in concurrent chemoradiation treatment of cervical carcinoma, in vitro and in vivo. (2014) (23)
Cooperativity of Cdk4R24C and Ras in melanoma development (2010) (23)
Molecular dissection of transcriptional control elements within the long terminal repeat of the retrovirus. (1984) (23)
Overexpression of C-terminally but not N-terminally truncated Myb induces fibrosarcomas: a novel nonhematopoietic target cell for the myb oncogene (1994) (22)
Dual Inhibition of CDK4/Rb and PI3K/AKT/mTOR Pathways by ON123300 Induces Synthetic Lethality in Mantle Cell Lymphomas (2015) (22)
Identification of alternatively spliced transcripts for human c-myb: molecular cloning and sequence analysis of human c-myb exon 9A sequences. (1989) (22)
Structural organization and chromosomal mapping of JAK3 locus. (1996) (22)
B cell differentiation: role of E2A and Pax5/BSAP transcription factors. (1995) (22)
Evaluation of novel cell cycle inhibitors in mantle cell lymphoma (2007) (21)
Regulation of HIV-1 gene expression by cellular transcription factors. (1992) (21)
Impaired adult myeloid progenitor CMP and GMP cell function in conditional c-myb-knockout mice (2012) (21)
A cDNA sequence encoding a rabbit heavy chain variable region of the VHa2 allotype showing homologies with human heavy chain sequences (1982) (21)
Nucleotide sequence analysis of the long terminal repeat of avian myeloblastosis virus and adjacent host sequences (1982) (20)
Design, synthesis, and biological evaluation of (E)- and (Z)-styryl-2-acetoxyphenyl sulfides and sulfones as cyclooxygenase-2 inhibitors. (2005) (20)
Identification of two translational products for c-myb. (1989) (20)
Identification of a novel Bcl-2 related gene, BRAG-1, in human glioma. (1996) (20)
Dual Targeting of CDK4 and ARK5 Using a Novel Kinase Inhibitor ON123300 Exerts Potent Anticancer Activity against Multiple Myeloma. (2016) (20)
Molecular Mechanisms Associated with the Regulation of Apoptosis by the Two Alternatively Spliced Products of c-Myb (2003) (20)
Translational Products of Moloney Murine Sarcoma Virus RNA: Identification of Proteins Encoded by the Murine Sarcoma Virus src Gene (1981) (19)
Increased angiogenesis in Cdk4R24C/R24C:Apc+/Min intestinal tumors (2010) (19)
Multi-unit anti-BCR-ABL ribozyme therapy in chronic myelogenous leukemia. (1996) (19)
Hydrothiolation of benzyl mercaptan to arylacetylene: application to the synthesis of (E) and (Z)-isomers of ON 01910·Na (Rigosertib®), a phase III clinical stage anti-cancer agent. (2013) (19)
Murine A-myb Gene Encodes a Transcription Factor, Which Cooperates with Ets-2 and Exhibits Distinctive Biochemical and Biological Activities from c-myb * (1997) (18)
Preclinical Pharmacokinetic and Pharmacodynamic Evaluation of Novel Anticancer Agents, ON01910.Na (Rigosertib, Estybon™) and ON013105, for Brain Tumor Chemotherapy (2012) (17)
Discovery of 2-(1H-indol-5-ylamino)-6-(2,4-difluorophenylsulfonyl)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one (7ao) as a potent selective inhibitor of Polo like kinase 2 (PLK2). (2016) (17)
Design, synthesis, and biological evaluation of (E)-N-aryl-2-arylethenesulfonamide analogues as potent and orally bioavailable microtubule-targeted anticancer agents. (2013) (17)
Preclinical Pharmacological Evaluation of a Novel Multiple Kinase Inhibitor, ON123300, in Brain Tumor Models (2014) (16)
Down-regulation of CD4 molecules by the expression of Nef: a quantitative analysis of CD4 antigens on the cell surfaces. (1993) (16)
Activation of the Jak3 pathway and myeloid differentiation (2005) (15)
Nucleotide sequence analysis of the long terminal repeat of integrated simian sarcoma virus: evolutionary relationship with other mammalian retroviral long terminal repeats (1982) (15)
c-Myc Is Essential but Not Sufficient for c-Myb-mediated Block of Granulocytic Differentiation* (2003) (15)
Requirement of Cdk4 for v-Ha-ras-Induced Breast Tumorigenesis and Activation of the v-ras-Induced Senescence Program by the R24C Mutation. (2010) (15)
Scintigraphic imaging of oncogenes with antisense probes: does it make sense? (1995) (15)
Granulocyte colony-stimulating factor-induced upregulation of Jak3 transcription during granulocytic differentiation is mediated by the cooperative action of Sp1 and Stat3 (2006) (14)
The Myb oncogene product induces DNA-bending. (1994) (14)
Genomic organization and characterization of the promoter region of murine GSTM2 gene. (2001) (14)
Aberrant expression of JNK-associated leucine-zipper protein, JLP, promotes accelerated growth of ovarian cancer (2016) (13)
Rauscher murine leukemia virus: molecular cloning of infectious integrated proviral DNA (1982) (12)
Neoplastic transformation induced by the gep oncogenes involves the scaffold protein JNK-interacting leucine zipper protein. (2011) (12)
Novel induction of CD40 expression by tumor cells with RAS/RAF/PI3K pathway inhibition augments response to checkpoint blockade (2021) (12)
p21 loss cooperates with INK4 inactivation facilitating immortalization and Bcl-2-mediated anchorage-independent growth of oncogene-transduced primary mouse fibroblasts. (2007) (12)
Murine myeloid leukemias with aberrant myb loci show heterogeneous expression of novel myb proteins. (1989) (12)
Identification and characterisation of a novel heat shock protein 90 inhibitor ONO4140. (2014) (11)
Transformation of chicken myelomonocytic cells by a retrovirus expressing the v-myb oncogene from the long terminal repeats of avian myeloblastosis virus but not Rous sarcoma virus (1992) (10)
Integrated Pharmacokinetic-Driven Approach to Screen Candidate Anticancer Drugs for Brain Tumor Chemotherapy (2012) (10)
Oncogenic mutant of Galpha12 stimulates cell proliferation through cycloxygenase-2 signaling pathway. (1999) (10)
Weighted Gene Co-Expression Network Analysis (WGCNA) Identifies Highly Proliferative Myeloma Subgroup Responsive to CDK4/ARK5 Inhibition (2014) (10)
A novel role of the scaffolding protein JLP in tuning CD40-induced activation of dendritic cells. (2013) (10)
A Contaminant Impurity, Not Rigosertib, Is a Tubulin Binding Agent. (2020) (9)
Cloning of murine G1RP, a novel gene related to Drosophila melanogaster g1. (2000) (9)
Transcriptional activation potential of normal and tumor-associated myb isoforms does not correlate with their ability to block GCSF-induced terminal differentiation of murine myeloid precursor cells. (1996) (9)
Structural alterations in the carboxyl-terminal domain of the BCRABL gene product activate its fibroblastic transforming potential. (1994) (8)
Alternative splicing of the chicken c-myb exon 9A. (1993) (8)
Large-scale molecular mapping of human c-myb locus: c-myb proto-oncogene is not involved in 6q- abnormalities of lymphoid tumors. (1992) (8)
JNK-associated Leucine Zipper Protein Functions as a Docking Platform for Polo-like Kinase 1 and Regulation of the Associating Transcription Factor Forkhead Box Protein K1* (2015) (8)
Single Cell Network Profiling (SCNP) to Evaluate the Mechanism of Action of ON 01910.Na, A Novel Clinical Trial Stage Compound. (2009) (7)
Solvent Dependent Dehydrating Condensation of Benzylsulfonyl Acetic Acids (2004) (7)
Disruption and activation of the c-myb locus by M-MULV insertion in plasmacytoid lymphosarcomas induced by pristane and Abelson viruses. (1984) (7)
Activated N-ras in a human rectal carcinoma cell line associated with clonal homozygosity in myb locus-restriction fragment polymorphism. (1986) (6)
Targeting protein kinase CK2 and CDK4/6 pathways with a multi-kinase inhibitor ON108110 suppresses pro-survival signaling and growth in mantle cell lymphoma and T-acute lymphoblastic leukemia (2018) (6)
Identification and characterization of a cell division-regulating kinase AKB1 (associated kinase of Trypanosoma brucei 14-3-3) through proteomics study of the Tb14-3-3 binding proteins. (2015) (6)
p89c‐Myb is not required for fetal or adult hematopoiesis (2010) (6)
Analyses of the splenic mRNA expressed by rabbits of different immunoglobulin kappa-light chain allotypes: conserved sequences in the 3' untranslated region and allotype-specific probes. (1983) (6)
Cross-resistance to ON01910.Na among drug-resistant human tumor cell lines (2006) (6)
Understanding the temporal sequence of genetic events that lead to prostate cancer progression and metastasis (2013) (6)
Mechanism of Activation of the myb Oncogene in Myeloid Leukemias a (1987) (6)
Evaluation of Rigosertib in Patients with a Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Relapsed or Refractory to Hypomethylating Agents: A Phase I/II Study (2010) (6)
Activation of the abl oncogene and its involvement in chromosomal translocations in human leukemia. (1988) (5)
The T Cell-Dependent B Cell Immune Response and Germinal Center Reaction Are Intact in A-myb-Deficient Mice1 (2001) (5)
Nuclear oncology and the Imagene concept. (1997) (5)
Sequential reduction and dehydration of phenacyl-(E)-styryl sulfones to unsymmetrical (E,E)-bis(styryl) sulfones (2005) (5)
Effect of Semicarpus anacardium on the cell cycle of DU-145 cells. (1998) (5)
The role of v-Fgr myristoylation and the Gag domain in membrane binding and cellular transformation. (1998) (5)
Screening candidate anticancer drugs for brain tumor chemotherapy: Pharmacokinetic-driven approach for a series of (E)-N-(substituted aryl)-3-(substituted phenyl)propenamide analogues (2012) (5)
Combined Administration of Rituximab and ON 013105 Induces Apoptosis in Mantle Cell Lymphoma Cells and Reduces Tumor Burden in a Mouse Model of Mantle Cell Lymphoma (2012) (4)
Immunoglobulin synthesis and gene rearrangements in lymphoid cells transformed by replication‐competent Rauscher murine leukemia virus: transformation of B cells at various stages of differentiation. (1984) (4)
Abstract LB-108: Targeting the Ras-Binding domain of RAS effector proteins by a small molecule inhibitor, Rigosertib (2014) (4)
Determination of the glucuronide metabolite of ON 013100, a benzylstyrylsulfone antineoplastic drug, in colon cancer cells using LC/MS/MS. (2013) (4)
Application of a liquid chromatography-tandem mass spectrometry (LC/MS/MS) method to the pharmacokinetics of ON01910 in brain tumor-bearing mice. (2011) (4)
Effects of a Novel Benzyl Styryl Sulfone Derivative ON 01910.Na On the Myelodysplastic Syndrome (MDS) Derived Clone in Patients Relapsing Following Response to Azacitidine (AzaC) Therapy. (2009) (4)
Therapeutics , Targets , and Chemical Biology Effect of ON 01910 . Na , an Anticancer Mitotic Inhibitor , on Cell-Cycle Progression Correlates with RanGAP 1 Hyperphosphorylation (2011) (3)
Mechanism of action of rigosertib does not involve tubulin binding (2019) (3)
Posiphen Reduces the Levels of Huntingtin Protein through Translation Suppression (2021) (3)
Rigosertib Blocks RAS Signaling By Acting As a Small Molecule RAS Mimetic That Binds to the RAS-Binding Domains of RAS Effector Proteins (2014) (3)
Inhibition of RNA-dependent DNA polymerase activity of oncornaviruses by caffeine. (1979) (3)
Rigosertib (RIG) in combination with azacitidine (AZA) to modulate epigenetic effects and to overcome clinical resistance to hypomethylating agents (HMA) in myelodsyplastic syndromes (MDS). (2016) (3)
Viruses and cancer of the immune system. (1989) (2)
Structural organization of mouse c-myb locus and the mechanism of its rearrangement in ABPL-2 tumor line induced by pristane and Abelson murine leukemia virus. (1984) (2)
Tumor Suppressor Genes (2002) (2)
CDK4 is an important target for hepatocellular cancer with inactivation of TGF-beta signaling through Smad and ELF (2008) (2)
Construction of a partial rabbit spleen cDNA library and identification of immunoglobulin clones (1982) (2)
Abstract 4519: Targeting of cyclin D/Rb/E2F and PI3K/AKT/MTOR pathways with ON 123300 as a therapeutic strategy for mantle cell lymphoma (2014) (2)
A cloned cDNA probe for rat immunoglobulin epsilon heavy chain: construction, identification, and DNA sequence. (1982) (2)
Nucleotide sequence of the simian sarcoma virus genome : Demonstration that its acquired cellular sequences encode the transforming gene product p 288 w ( primate retrovirus / antisera to synthetic peptides / transforming protein ) (2)
Mutational analysis of Max (1992) (2)
Synergistic Effects of a Novel Water-Soluble Small Molecule, ON 013105, and Rituximab on Mantle Cell Lymphoma In Vitro and In Vivo (2010) (2)
Murine myeloid leukemic cells with disrupted myb loci show splicing anomalies that account for heterogeneous sizes in myb proteins. (1996) (2)
126 : Inhibition of Survivin Phosphorylation by On01910, A Novel Benzylstyryl Sulfone, Promotes Radiation Sensitization in Androgen Independent Human Prostate Carcinoma Cells (2006) (1)
Abstract 4595: RPL18A as putative target of rigosertib (2014) (1)
Effects of Rigosertib (RIGO) Alone or in Combination with Azacitidine or Vorinostat on Epigenetic Reprogramming of CD34+ Cells in the Myelodysplastic Syndrome (2017) (1)
Abstract 2500: ON 01910. Na, a clinical stage anticancer mitotic inhibitor, produces prolonged hyperphosphorylation of RanGAP1•SUMO1 as a potential mechanism of G2/M arrest and apoptosis (2010) (1)
Transformation of NIH3T3 cells by A-MuLV proviral DNA: effect of plasmid linearization and carrier DNA on transformation efficiency. (1989) (1)
Abrogation of IL-2 dependence by recombinant murine retrovirus containing v-myb. (1992) (1)
Sequential Reduction and Dehydration of Phenacyl‐(E)‐styryl Sulfones to Unsymmetrical (E,E)‐Bis(styryl) Sulfones. (2006) (1)
Abstract 2639: RanGAP1·SUMO1 hyperphosphorylation (RGSH) and mitotic arrest by ON 01910.Na, okadaic acid or tubulin agents (2011) (1)
PS1332 RIGOSERTIB MODULATES HEMATOPOIESIS GENE SIGNALING PATHWAYS ALONE OR IN SEQUENCED COMBINATION WITH AZACTIDINE ON MDS CELLS IN VITRO (2019) (1)
Nucleotide sequence and organization of the transforming region and large terminal redundancies (LTR) of avian myeloblastosis virus (AMV) (1982) (1)
Predictors Of Response To Rigosertib In Patients With a Myelodysplastic Syndrome (MDS) Or Acute Myeloid Leukemia (AML) Relapsing After Or Refractory To Hypomethylating Agents (2013) (1)
Abstract 4453: The dual CK2/TNIK inhibitor, ON108600 targets cancer stem cells and induces apoptosis of paclitaxel resistant triple-negative breast cancer cells (2015) (1)
Abstract #3717: Identification of a dual JAK-2/BCR-ABL kinase inhibitor for treatment of myeloproliferative disorders (2009) (1)
Recombinant virus coat protein associated with "Acquired Immune Deficiency Syndrome" (AIDS), and methods for testing of AIDS. (1986) (1)
Oncogenes and Protooncogenes (2002) (1)
Nucleotide sequence ofthetransforming geneofsimian sarcoma virus (1982) (1)
Mechanisms in interleukin 3 regulated growth and differentiation. (1987) (1)
Escape from Cellular Senescence Mutation Facilitates Tumorigenesis and R24C Cdk4 Germ Line Transmission of the (2014) (1)
Cytotoxicity and Radiosensitization in Cervical Carcinoma Cells by ON01910, a Novel Polo-Like Kinase 1 Inhibitor (2005) (1)
Radiation sensitization of prostate carcinoma cells by ONC 01910, a novel protein kinase inhibitor and cell cycle modulator (2004) (1)
Abstract 3029: Dual targeting of ARK5 and CDK4 pathways with ON 123300 as a therapeutic strategy for colorectal carcinoma (2016) (1)
Dual inhibition of JAK2V617F and BCR-ABLT315I by a novel class of non-ATP competitive kinase inhibitors (2007) (0)
combination (45). Abelson MuLV, like (0)
Abstract 694: Structure-function analysis of RPL18A, a putative binding target of rigosertib (2015) (0)
In vitro comparative efficacy of ON01910.Na and cisplatin with radiation on cervical carcinoma cells (2008) (0)
Abstract 3026: Rigosertib (RIG) modulates MAPK and hematopoiesis signaling and synergizes Azacitidine (AZA) altering viral mimicry pathway in myelodysplastic syndrome (MDS) (2019) (0)
Interaction of JLP with Plk1 recruits FoxK1 to interact and form a ternary complex (2014) (0)
Substituted phenoxy and phenylthioderivater for the treatment of proliferative disorders (2005) (0)
Folate-Polylysine-Mediated Delivery of a Multiunit Anti-BCR/ABL Ribozyme to BCR/ABL-Transformed 32D Cells (1998) (0)
8-alkyl-7-oxo-7,8-dihydropyrido [2,3-d] pyrimidine-6-carbonitriles and 2-substituted uses thereof (2011) (0)
Haploinsufficiency of CDK4 prevents hepatocarcinogenesis in mice deficient in ELF, a mediator of TGF-beta signaling (2007) (0)
Correction: critical interactions between TGF-β signaling/ELF, and E-cadherin/β-catenin mediated tumor suppression (2021) (0)
Aberrant Wnt/β-catenin signaling in TGF-β pathway elf+/-, and elf+/-/smad3+/- mutant mouse models of human Beckwith- Wiedemann Syndrome (2008) (0)
Oncogenes and the Nobel Prize. (1990) (0)
Genetic approaches toward elucidating the mechanisms of type-C virus-induced leukemia. (1981) (0)
Agents anticancer au (e)-styrylsulfone (2000) (0)
Intact in A-myb-Deficient Mice Response and Germinal Center Reaction Are The T Cell-Dependent B Cell Immune (2001) (0)
Higher Efficacy of ON01910.Na as a Potent Radiosensitizer than Cisplatin on Human Cervical Carcinoma Cells (2008) (0)
A Small Molecule RAS-Mimetic Disrupts RAS Associationwith Effector Proteins to Block Signaling Graphical (0)
Synthesis and biological evaluation of Z-isomers of Rigosertib® (ON 01910.Na) - A clinical stage (Phase III) multi kinase anti-cancer agent. (2012) (0)
Mechanisms of Resistance to Targeted Tyrosine Kinase Inhibitors (2009) (0)
Ribozyme mediated therapy for chronic myelogenous leukemia. (1994) (0)
Mechanisms of Resistance to Targeted B-Raf Therapies (2013) (0)
Phenoxy and phenylthio derivatives substituted for treating proliferative disorders (2005) (0)
Targeting oncogenic STAT3 and STAT5 signaling with on 146040, a small molecule inhibitor of PI3K α/δ and BCR-ABL. (2014) (0)
Evaluation of Novel Cell Cycle Inhibitors in Mantle Cell Lymphoma. (2006) (0)
Novel COX-2 Inhibitor for Breast Cancer Therapy (2005) (0)
Abstract 1578: Heating it up: Targeting RAS/RAF/PI3K pathway to make melanoma tumors ‘immunologically hot' and suitable for checkpoint blockade immunotherapies (2021) (0)
Mitogen-Activated Protein Kinases and Their Scaffolding Proteins (2010) (0)
Award Number: W81XWH-06-1-0267 TITLE: A Non-ATP Competitive Inhibitor of BCR-ABL for the Therapy of Imatinib- Resistant Cmls (2008) (0)
Tumor Necrosis Factor Ligand Superfamily : Involvment in the Pathology of Malig nant Lymphomas ' (2017) (0)
Abstract 643: Targeting cancer with a selective ATP-mimetic inhibitor of polo like kinase-2 (2011) (0)
Preclinical Pharmacokinetic and Pharmacodynamic Evaluation of Novel Anticancer Agents, ON01910.Na (Rigosertib, Estybon™) and ON013105, for Brain Tumor Chemotherapy (2012) (0)
Substituted styrylbenzylsulfoner for the treatment of proliferative diseases (2001) (0)
An In Vivo Functional Screen Identifies miRNA-150 As a Regulator of Hematopoietic Regeneration Post Chemotherapeutic Injury (2011) (0)
Integrated Pharmacokinetic-Driven Approach to Screen Candidate Anticancer Drugs for Brain Tumor Chemotherapy (2012) (0)
Abstract P5-05-04: A novel inhibitor of cancer stem cells overcomes chemotherapy resistance of triple negative breast cancers (2020) (0)
Chromosomal mapping ofthesimian sarcoma virus oncgene analogue inhumancells (1982) (0)
Abstract 4595: RPL18A as putative target of (2014) (0)
Abstract 2450: Identifying novel substrates of PLK2 using a chemical genetics approach (2015) (0)
Retroviral oncogenes and human neoplasia. (1985) (0)
Nucleotide Sequence Analysis of Integrated Avian Myeloblastosis Virus (AMV) Long Terminal Repeat (LTR) and Their Host and Viral Junctions: Structural Similarities to Transposable Elements (1983) (0)
Sequential Treatment with Rigosertib Followed By Azacitidine Maximizes the Effects on the Interferon Signaling Pathway in Hematopoietic Cells in Myelodysplastic Syndrome (MDS) (2018) (0)
Abstract 695: Glucuronidation in human colon cancer cells acts as an intrinsic mechanism of resistance against tubulin depolymerizers that are UGT substrates (2011) (0)
Solvent Dependent Dehydrating Condensation of Benzylsulfonyl Acetic Acids. (2004) (0)
Rigosertib in Combination with Azacitidine Modulates Epigenetic Pathways and can Overcome Clinical Resistance to Hypomethylating Agents in Myelodysplastic Syndromes (MDS) (2017) (0)
The Sequenced Combination of Rigosertib and Azacitidine Has Modulatory Effects on CXCL8, RIG-I like Receptor (RLR) and Wnt/β-Catenin Signaling and Downstream Hematopoiesis Pathways in an in Vitro Model of the Myelodysplastic Syndrome (2019) (0)
Structure and mechanism of activation of the myb oncogene. (1986) (0)
ON012380: A Non-ATP Competitive Inhibitor of BCR-ABL for the Therapy of Imatinib-Resistant CMLs (2009) (0)
L08.04RIGOSERTIB IS A MORE EFFECTIVE RADIOSENSITIZER THAN CISPLATIN IN CONCURRENT CHEMO-RADIATION TREATMENT OF CERVICAL CARCINOMA, IN VITRO AND IN VIVO (2013) (0)
Combination of Ras Modulator and Azacitidine Impacts Innate Immune Signaling Pathway in MDS-L Cell Line (2021) (0)
P-274 Rigosertib activity in patients with a myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) relapsed or refractory to hypomethylating agents (2013) (0)
Rigosertib in Combination with Azacitidine Impacts Metabolic and Differentiation Pathways in the MDS-L Cell Line (2020) (0)
Abstract 3239: Discovery and biological characterization of ON108600, a small molecule inhibitor of protein kinase CK2. (2013) (0)
Nucleotide sequence analysis of the transforming region and large terminal redundancies of Moloney murine sarcoma virus ( src sequence / open reading frame / inverted repeats / transposable elements ) (0)
Abstract A41: Targeting the ARK5/MYC axis to develop second generation CDK4/6 inhibitors (2015) (0)
Antisense Deoxynucleotides and Ribozymes: Mechanisms of Action and Potential in Gene Therapy (2021) (0)
Abstract 3797: Hyperphosphorylation and desumoylation of RanGAP1·SUMO1 (2012) (0)
A-Myb In Development And Cancer (2004) (0)
Abstract 1324: Dual targeting of CDK4 and ARK5 using a novel kinase inhibitor ON123300 is effective in vitro and in vivo in Multiple Myeloma (2014) (0)
AD Award Number : DAMD 17-021-0579 TITLE : Novel Cox-2 Inhibitor for Breast Cancer Therapy (0)
Influence of human serum albumin on cytotoxic activity of ON01910.Na (2005) (0)
Abstract LB-110: CDK4 activation is a key step in ELF alteration and haploinsufficeny ofcdk4prevents HCC formation inelf+/−mice (2010) (0)
Spontaneous activation of a human proto-oncogene ( malignant transformation / cha / bas gene / point mutation / 12 th codon / aspartic acid ) (0)
The transforming gene of avian myeloblastosis virus (AMV): nucleotide sequence analysis and identification of its translational product. (1983) (0)
Abstract 2094: Dual inhibition of FLT3 and Src pathways by ON150030, a type 1 inhibitor, as a novel strategy for relapsed and refractory AML therapy (2017) (0)

This paper list is powered by the following services:

Other Resources About E. Premkumar Reddy

en.wikipedia.org

What Schools Are Affiliated With E. Premkumar Reddy?

E. Premkumar Reddy is affiliated with the following schools:

E. Premkumar Reddy's Academic­Influence.com Rankings

E. Premkumar Reddy's Degrees

Why Is E. Premkumar Reddy Influential?

E. Premkumar Reddy's Published Works

Published Works

Other Resources About E. Premkumar Reddy

What Schools Are Affiliated With E. Premkumar Reddy?

E. Premkumar Reddy's AcademicInfluence.com Rankings